Brokerages Set Insys Therapeutics Inc (INSY) PT at $7.67

Insys Therapeutics Inc (NASDAQ:INSY) has been given an average rating of “Hold” by the seven analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $7.67.

A number of brokerages recently issued reports on INSY. ValuEngine raised Insys Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, August 15th. Zacks Investment Research lowered Insys Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 15th. Royal Bank of Canada reissued a “buy” rating and set a $9.00 price target on shares of Insys Therapeutics in a research note on Thursday, August 9th. Piper Jaffray Companies set a $4.00 target price on Insys Therapeutics and gave the company a “sell” rating in a research report on Saturday, August 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $10.00 target price on shares of Insys Therapeutics in a research report on Friday, August 10th.

Shares of INSY stock opened at $8.33 on Friday. Insys Therapeutics has a 52-week low of $4.10 and a 52-week high of $14.00. The company has a market cap of $566.49 million, a P/E ratio of -17.00 and a beta of 1.65.

Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.17). Insys Therapeutics had a negative return on equity of 130.43% and a negative net margin of 238.31%. The business had revenue of $23.47 million for the quarter, compared to the consensus estimate of $25.91 million. During the same period in the prior year, the business posted $0.03 earnings per share. Insys Therapeutics’s revenue was down 44.9% on a year-over-year basis. On average, analysts anticipate that Insys Therapeutics will post -1.24 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Creative Planning bought a new stake in Insys Therapeutics during the 3rd quarter valued at $153,000. Northern Trust Corp raised its position in Insys Therapeutics by 10.1% during the 2nd quarter. Northern Trust Corp now owns 348,334 shares of the specialty pharmaceutical company’s stock valued at $2,522,000 after purchasing an additional 32,009 shares in the last quarter. Millennium Management LLC bought a new stake in Insys Therapeutics during the 2nd quarter valued at $1,232,000. Tower Research Capital LLC TRC bought a new stake in Insys Therapeutics during the 2nd quarter valued at $131,000. Finally, BlackRock Inc. raised its position in Insys Therapeutics by 7.9% during the 2nd quarter. BlackRock Inc. now owns 2,637,505 shares of the specialty pharmaceutical company’s stock valued at $19,096,000 after purchasing an additional 193,740 shares in the last quarter. 18.02% of the stock is owned by institutional investors and hedge funds.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.

Recommended Story: What is a stock split?

Analyst Recommendations for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply